DCGI approves Dr Reddy's request to conduct Phase 2, 3 clinical trials with Russia's Sputnik V COVD-19 vaccine
RDIF will also supply 100 million doses of Dr Reddy's after receiving Indian regulatory approval.
COVID-19 recoveries continue to surpass new cases; next two-and-a-half month period crucial says Harsh Vardhan
The health ministry also said on Friday that India has one of the lowest COVID-19 deaths per million population in the world, with less than 1,000 fatalities registered daily since 4 October,
Dr Reddy's asked to resubmit phase 2,3 trial application for Russia's Sputnik V COVID-19 vaccine by DCGI
Dr Reddy's trials will have to be first assessed in a small group of volunteers to study its efficacy before it can be tested on a larger population.
RDIF, Dr Reddy's Lab tie up for Sputnik V human trials, distribution of 100 mn doses of the COVID-19 vaccine in India
As of 1 August, Phase I and II of the vaccine were complete and by 11 August, Russian President Vladimir Putin had registered it as the world's first vaccine.
The Serum Institute of India, which had paused phase 2 and phase 3 trials of the Oxford University's vaccine, received the go-ahead from the DCGI to resume the trials in India
Coronavirus Updates: Maharashtra reports 14,492 new COVID-19 cases, 326 deaths; tally rises to 6,43,289
Coronavirus LIVE Updates: As many as 26 volunteers who reached the Air-India Express plane crash site in Kozhikode evacuated the injured passengers on 7 August, have tested positive for COVID-19
Govt's unlock Phase 1.0 enthuses markets: Sensex soars 879 points, Nifty jumps to 9,800-level; Bajaj Finance top gainer at around 11%
The Sensex surged driven by gains in Reliance Industries, HDFC twins and TCS as investor optimism heightened after the government began the process of unlocking the economy.
Dr Reddy's Q4 profit jumps 76% to Rs 764 cr on higher sales in US, Europe; revenue up 10% at Rs 4,432 cr
Dr Reddy's said various initiatives have been undertaken to ensure that our manufacturing-related operations continue unabated enabling it to serve the patients.
Dr Reddy's Labs to acquire branded generics business of Wockhardt for Rs 1,850 cr; deal to help scale-up presence in home market
Dr Reddy's will acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives.
Real bank credit growth drops drastically, UTI AMC IPO could not have been better timed; all this and more on Moneycontrol Pro
Despite the loan melas and multiple rate cuts, bank credit continues to remain sluggish.
India pharma majors Dr Reddy's, Wockhardt, and others deny allegations of conspiracy to fix prices in US
The generic drug makers are named in an anti-trust lawsuit in the US on allegations of engaging in a conspiracy to fix prices
Stock markets expected to perform better in 2019; here are 10 stocks that could give good returns in 2019
We believe the markets will be likely in a consolidation mode going forward with some correction that can bring down the valuations to a cheaper level. Risk aversion will be the flavor
Pharma sector may post 17% revenue growth in June quarter; domestic growth, currency tailwinds to drive growth: Report
The domestic pharmaceutical sector accounts for 3.1-3.6 percent of the global pharmaceutical industry in value terms and 10 percent in volume terms.
Sensex down 102 points in cautious trade, slips below 35,000 mark; power, banking, realty stocks decline; Re dips
Sensex, which had lost 310.49 points in the previous two sessions, fell further by 101.70 points, or 0.29 percent, to 34,910.19.
Sensex slides 214 points on global cues, Nifty cracks below 10,600 mark; auto, bank stocks major losers
The 30-share index, which had lost 216.24 points in the previous session, drifted down by 214.13 points, or 0.61 percent, to 34,735.11.
Sensex opens higher over 53 points despite weak macro data ahead of Karnataka Assembly poll results; Re gains 12 paise
Sensex which had gained 289.52 points in the previous session, was trading higher by 53.21 points, or 0.14 percent, at 35,589, with realty, oil and gas, healthcare, PSU, banking and capital goods stocks leading the gains.
Stocks of Punjab National Bank which had been under selling pressure since the massive fraud detection, however, edged 1.05 percent higher.
Nifty crosses 10,600 mark for the first time, while Sensex soars to 34,331; pharma, IT, banking stocks gain
The 30-share Sensex soared by 178 points, or 0.52 percent, to 34,331.85 points, breaching its previous record high (intra-day) of 34,188.85 hit on 5 January.
The benchmark BSE Sensex was trading higher by 101.89 points or 0.30 percent at 33,895.27
Among the sectoral indices, realty was the hardest hit, down 4.53 percent